We are excited to announce that PharmaBlock has been listed in the“Forbes Asia’s Best Under A Billion 2021". The list identifies companies with long-term excellence across a variety of measures. From a universe of 20,000 publicly traded companies in the Asia-Pacific region with annual revenue above $10 million and below $1 billion, only 200 companies were selected. PharmaBlock keeps steady growth even under the epidemic, and its ever-changing mission is to provide better products and services through innovation of chemistry and low carbon technology in R&D and manufacturing, and eventually to support partners to accelerate drug discovery and development, and move the new molecules into the market at full speed.